Long non-coding rna pandar as an independent prognostic marker in cancer

Recently, long noncoding RNAs (lncRNAs) have been shown to be involve in regulation of different biological processes, such as cell growth, differentiation and tumorigenesis. They are proposed to bepromising clinical biomarkers in various tumors. Long noncoding RNA promoter of CDKN1A antisense DNA damage activated RNA (PANDAR) has been reported to be aberrantly expressed in many types of cancers. This meta-analysis collected all relevant articles and explored correlation of PANDAR with overall survival (OS) and other clincopathological parameters. A quantitative meta- analysis was performed through a systematic search in PubMed, Web of Science, Medline, and the Cochrane Library. The hazard ratio (HR) of OS, along with the odds ratios (OR) of lymph node metastasis (LNM), distant metastasis (DM) and tumor stage were calculated to assess the association strength. eight studies with a total of 975 patients affected by different types of cancer including; 1 clear cell renal cell carcinoma (ccRCC), 1 cholangiocarcinoma (CCA), 2 colorectal cancer (CRC), 1 bladder cancer (BC), 1 pancreatic ductal adenocarcinoma (PDAC), 1 hepatocellular carcinoma (HCC), 1 non- small cell lung cancer (NSCLC) and 1 gastric cancer (GC) were included in the meta-analysis. Compared with low PANDAR expression, high PANDAR expression correlated with poorer OS (pooled HR 2.78, 95% CI: 2.02–3.82, p<0.001). A similar result was found between PANDAR expression and cancer clinicopathological features, such as LNM (OR=2.79, 95% CI: 1.81-4.32, p<0.001), DM and tumor stage. These results suggested that lncRNA-PANDAR may be served as a biomarker for cancer metastasis and prognosis.